Twenty years ago, behavioral economics did not exist as a field. Most economists were deeply skeptical--even antagonistic--toward the idea of importing insights from psychology into their field. Today, behavioral economics has become virtually mainstream. It is well represented in prominent journals and top economics departments, and behavioral economists, including several contributors to this volume, have garnered some of the most prestigious awards in the profession.

This book assembles the most important papers on behavioral economics published since around 1990. Among the 25 articles are many that update and extend earlier foundational contributions, as well as cutting-edge papers that break new theoretical and empirical ground.

"Advances in Behavioral Economics" will serve as the definitive one-volume resource for those who want to familiarize themselves with the new field or keep up-to-date with the latest developments. It will not only be a core text for students, but will be consulted widely by professional economists, as well as psychologists and social scientists with an interest in how behavioral insights are being applied in economics.

The articles, which follow Colin Camerer and George Loewenstein's introduction, are by the editors, George A. Akerlof, Linda Babcock, Shlomo Benartzi, Vincent P. Crawford, Peter Diamond, Ernst Fehr, Robert H. Frank, Shane Frederick, Simon Gachter, David Genesove, Itzhak Gilboa, Uri Gneezy, Robert M. Hutchens, Daniel Kahneman, Jack L. Knetsch, David Laibson, Christopher Mayer, Terrance Odean, Ted O'Donoghue, Aldo Rustichini, David Schmeidler, Klaus M. Schmidt, Eldar Shafir, Hersh M. Shefrin, Chris Starmer, Richard H. Thaler, Amos Tversky, and Janet L. Yellen."

This monograph consists of five chapters that describe the diagnosis and treatment of oral squamous cell carcinoma (OSCC), which is the most common malignant epithelial neoplasm affecting the oral cavity. Chapter One deals with different potentially malignant disorders in the development of OSCC, diagnostic methods of OSCC, the pertinence of biomarkers in OSCC therapy, classification of biomarkers, existing biomarkers in different stages of OSCC and the challenges of developing new biomarkers. Chapter Two is focused on principles, systems, technologies, therapeutic approaches, safety and toxicity and patents comprising drug delivery systems for local oral squamous cell carcinoma treatment. Chapter Three aims to highlight a detailed critical review of previous literature on putative cancer stem cell pathways for oral carcinoma and draw interest in targeting the most common cancer stem cell markers as a therapeutic regimen for oral cancer preneoplastic tumors, metastasis, and treatment progression. Chapter Four aims to cover the recent developments in nanotechnology-based drug delivery systems, advanced nanomedicines and their diagnostics as well as therapeutic applications in OSCC. Finally, Chapter 5 aims to elaborate on the importance of biomarkers as an early diagnostic tool in detecting oral squamous cell carcinoma.